Ipsen media releases

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 26 Press Releases

Show

Sort

23 October 2025

23 October 2025

Download Ipsen launches educational initiative to support teens and young adults moving from pediatric to adult healthcare

Ipsen launches educational initiative to support teens and young adults moving from pediatric to adult healthcare

18 November 2024

18 November 2024

Download Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

15 November 2024

15 November 2024

Download Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

10 June 2024

10 June 2024

Download Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

05 June 2024

05 June 2024

Download Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis